Adipokines, biomarkers of endothelial activation, and metabolic syndrome in patients with ankylosing spondylitis

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Genre, Fernanda ^a   López Mejías, Raquel ^a   Miranda Filloy, José A ^b   Ubilla, Begoña ^a   Carnero López, Beatriz ^c   Blanco, Ricardo ^a   Pina, Trinitario ^a   González Juanatey, Carlos ^b   Llorca, Javier ^d   González Gay, Miguel A ^a  

^a IDIVAL   (Spain)

^b Hospital Lucus Augusti   (Spain)

^c HOSPITAL EL BIERZO   (Spain)

^d UNIVERSITY OF CANTABRIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ANGIOPOIETIN 2; APELIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; GELSOLIN; GHRELIN; GHRELIN RECEPTOR; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 12; INTERLEUKIN 4; INTERLEUKIN 6; LEPTIN; N(G),N(G) DIMETHYLARGININE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OSTEOPONTIN; OSTEOPROTEGERIN; RESISTIN; RETINOL BINDING PROTEIN 4; TUMOR NECROSIS FACTOR ALPHA; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ANKYLOSING SPONDYLITIS; CARDIOVASCULAR RISK; CELL ACTIVATION; CYTOKINE PRODUCTION; ENDOTHELIUM CELL; HUMAN; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; METABOLIC SYNDROME X; PROTEIN BLOOD LEVEL; REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; COMPLICATION; METABOLISM; PATHOLOGY; RISK FACTOR; SPONDYLITIS, ANKYLOSING; VASCULAR ENDOTHELIUM;

ADIPOKINES; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; BIOLOGICAL MARKERS; ENDOTHELIUM, VASCULAR; HUMANS; METABOLIC SYNDROME X; RISK FACTORS; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84897523034     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/860651     Document Type: Review

References (121)

1. El Maghraoui A., Extra-articular manifestations of ankylosing spondylitis: prevalence, characteristics and therapeutic implications. European Journal of Internal Medicine 2011 22 6 554 560 2-s2.0-80855131442 10.1016/j.ejim.2011.06.006
2. Braun J., van den Berg R., Baraliakos X., Boehm H., Burgos-Vargas R., Collantes-Estevez E., Dagfinrud H., Dijkmans B., Dougados M., Emery P., Geher P., Hammoudeh M., Inman R. D., Jongkees M., Khan M. A., Kiltz U., Kvien T. K., Leirisalo-Repo M., Maksymowych W. P., Olivieri I., Pavelka K., Sieper J., Stanislawska-Biernat E., Wendling D., Özgocmen S., van Drogen C., van Royen B. J., van der Heijde D., 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Annals of the Rheumatic Diseases 2011 70 6 896 904 2-s2.0-79955826864 10.1136/ard.2011.151027
3. Gonzalez-Juanatey C., Vazquez-Rodriguez T. R., Miranda-Filloy J. A., Dierssen T., Vaqueiro I., Blanco R., Martin J., Llorca J., Gonzalez-Gay M. A., The high prevalence of subclinical atherosclerosis in patients with ankylosing spondylitis without clinically evident cardiovascular disease. Medicine 2009 88 6 358 365 2-s2.0-72949099950 10.1097/MD.0b013e3181c10773
4. Mathieu S., Motreff P., Soubrier M., Spondyloarthropathies: an independent cardiovascular risk factor? Joint Bone Spine 2010 77 6 542 545 2-s2.0-78649907560 10.1016/j.jbspin.2010.05.001
5. Deng Y., Scherer P. E., Adipokines as novel biomarkers and regulators of the metabolic syndrome. Annals of the New York Academy of Sciences 2010 1212 E1 E19 2-s2.0-79952259618
6. Procaccini C., de Rosa V., Galgani M., Role of adipokines signaling in the modulation of T cells function. Frontiers in Immunology 2013 4 332 10.3389/fimmu.2013.00332
7. Shoelson S. E., Lee J., Goldfine A. B., Inflammation and insulin resistance. Journal of Clinical Investigation 2006 116 7 1793 1801 2-s2.0-33745861300 10.1172/JCI29069
8. Kim J. A., Montagnani M., Kwang K. K., Quon M. J., Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 2006 113 15 1888 1904 2-s2.0-33646178955 10.1161/CIRCULATIONAHA.105.563213 (Pubitemid 43739401)
9. Cersosimo E., DeFronzo R. A., Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases. Diabetes/Metabolism Research and Reviews 2006 22 6 423 436 2-s2.0-33745948085 10.1002/dmrr.634 (Pubitemid 44774046)
10. Sari I., Okan T., Akar S., Cece H., Altay C., Secil M., Birlik M., Onen F., Akkoc N., Impaired endothelial function in patients with ankylosing spondylitis. Rheumatology 2006 45 3 283 286 2-s2.0-33644856098 10.1093/rheumatology/kei145 (Pubitemid 43372841)
11. D'Angelo S., Palazzi C., Cantini F., Lubrano E., Marchesoni A., Mathieu A., Salvarani C., Scarpa R., Spadaro A., Olivieri I., Etanercept in spondyloarthropathies. Part II. Safety and pharmacoeconomic issues. Clinical and Experimental Rheumatology 2011 29 5 865 870 2-s2.0-83455229794
12. Palazzi C., D'Angelo S., Cantini F., Lubrano E., Marchesoni A., Mathieu A., Salvarani C., Scarpa R., Spadaro A., Olivieri I., Etanercept in spondyloarthropathies. Part I. Current evidence of efficacy. Clinical and Experimental Rheumatology 2011 29 5 858 864 2-s2.0-83455173656
13. Heldmann F., Brandt J., van der Horst-Bruinsma I. E., Landewe R., Sieper J., Burmester G. R., van den Bosch F., de Vlam K., Geusens P., Gaston H., Schewe S., Appelboom T., Emery P., Dougados M., Leirisalo-Repo M., Breban M., Listing J., Braun J., The European ankylosing spondylitis infliximab cohort (EASIC): a European multicentre study of long term outcomes in patients with ankylosing spondylitis treated with infliximab. Clinical and experimental rheumatology 2011 29 4 672 680 2-s2.0-80055097919
14. Smolen J. S., Emery P., Infliximab: 12 years of experience. Arthritis Research and Therapy 2011 13 1, article S2 2-s2.0-79958145733 10.1186/1478-6354-13-S1-S2
15. Syngle A., Vohra K., Sharma A., Kaur L., Endothelial dysfunction in ankylosing spondylitis improves after tumor necrosis factor- α blockade. Clinical Rheumatology 2010 29 7 763 770 2-s2.0-77956268191 10.1007/s10067-010- 1402-x
16. Miranda-Filloy J. A., Llorca J., Carnero-López B., González-Juanatey C., Blanco R., González-Gay M. A., TNF- α antagonist therapy improves insulin sensitivity in non-diabetic ankylosing spondylitis patients. Clinical Experimental and Rheumatology 2012 30 6 850 855
17. Gonzalez-Gay M. A., de Matias J. M., Gonzalez-Juanatey C., Garcia-Porrua C., Sanchez-Andrade A., Martin J., Llorca J., Anti-tumor necrosis factor- α blockade improves insulin resistance in patients with rheumatoid arthritis. Clinical and Experimental Rheumatology 2006 24 1 83 86 2-s2.0-33645082929
18. Gonzalez-Gay M. A., Gonzalez-Juanatey C., Vazquez-Rodriguez T. R., Miranda-Filloy J. A., Llorca J., Insulin resistance in rheumatoid arthritis: the impact of the anti-TNF- α therapy. Annals of the New York Academy of Sciences 2010 1193 153 159 2-s2.0-77951227180 10.1111/j.1749-6632.2009.05287.x
19. Baatar D., Patel K., Taub D. D., The effects of ghrelin on inflammation and the immune system. Molecular and Cellular Endocrinology 2011 340 1 44 58 2-s2.0-79958082780 10.1016/j.mce.2011.04.019
20. Dixit V. D., Schaffer E. M., Pyle R. S., Collins G. D., Sakthivel S. K., Palaniappan R., Lillard J. W. Jr., Taub D. D., Ghrelin inhibits leptin- and activation-induced proinflammatory cytokine expression by human monocytes and T cells. Journal of Clinical Investigation 2004 114 1 57 66 2-s2.0-3242749843 10.1172/JCI200421134 (Pubitemid 39071644)
21. Tschöp M., Weyer C., Tataranni P. A., Devanarayan V., Ravussin E., Heiman M. L., Circulating ghrelin levels are decreased in human obesity. Diabetes 2001 50 4 707 709 2-s2.0-0035082265 (Pubitemid 32242624)
22. Genre F., López-Mejias R., Miranda-Filloy J. A., Correlation between insulin resistance and serum ghrelin in non-diabetic ankylosing spondylitis patients undergoing anti-TNF- α therapy. Clinical and Experimental Rheumatology 2013 31 6 913 918
23. Pöykkö S. M., Kellokoski E., Hörkkö S., Kauma H., Kesäniemi Y. A., Ukkola O., Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes. Diabetes 2003 52 10 2546 2553 2-s2.0-0141643291 10.2337/diabetes.52.10.2546 (Pubitemid 37210544)
24. Lazar M. A., Resistin- and obesity-associated metabolic diseases. Hormone and Metabolic Research 2007 39 10 710 716 2-s2.0-36048981001 10.1055/s-2007-985897 (Pubitemid 350099817)
25. Toussirot É., Streit G., Nguyen N. U., Dumoulin G., le Huédé G., Saas P., Wendling D., Adipose tissue, serum adipokines, and ghrelin in patients with ankylosing spondylitis. Metabolism 2007 56 10 1383 1389 2-s2.0-34548633198 10.1016/j.metabol.2007.05.009 (Pubitemid 47404601)
26. Otero M., Nogueiras R., Lago F., Dieguez C., Gomez-Reino J. J., Gualillo O., Chronic inflammation modulates ghrelin levels in humans and rats. Rheumatology 2004 43 3 306 310 2-s2.0-1542299619 10.1093/rheumatology/keh055 (Pubitemid 38313178)
27. Gonzalez-Gay M. A., Garcia-Unzueta M. T., Berja A., Vazquez-Rodriguez T. R., Gonzalez-Juanatey C., De Matias J. M., Martin J., Dessein P. H., Llorca J., Anti-tumour necrosis factor α therapy modulates ghrelin in patients with severe rheumatoid arthritis. Annals of the Rheumatic Diseases 2008 67 11 1644 1646 2-s2.0-54349118245 10.1136/ard.2008.088773
28. Kwon H., Pessin J. E., Adipokines mediate inflammation and insulin resistance. Frontiers in Endocrinology 2013 4, article 71 10.3389/fendo.2013. 00071
29. Graham T. E., Yang Q., Blüher M., Hammarstedt A., Ciaraldi T. P., Henry R. R., Wason C. J., Oberbach A., Jansson P.-A., Smith U., Kahn B. B., Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. The New England Journal of Medicine 2006 354 24 2552 2563 2-s2.0-33745095399 10.1056/NEJMoa054862 (Pubitemid 43882351)
30. Gavi S., Stuart L. M., Kelly P., Melendez M. M., Mynarcik D. C., Gelato M. C., McNurlan M. A., Retinol-binding protein 4 is associated with insulin resistance and body fat distribution in nonobese subjects without type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 2007 92 5 1886 1890 2-s2.0-34249860936 10.1210/jc.2006-1815 (Pubitemid 46997205)
31. Christou G. A., Tselepis A. D., Kiortsis D. N., The metabolic role of retinol binding protein 4: an update. Hormone and Metabolic Research 2012 44 1 6 14 2-s2.0-84855256757 10.1055/s-0031-1295491
32. Genre F., López-Mejías R., Miranda-Filloy J. A., Antitumour necrosis factor- α treatment reduces retinol-binding protein 4 serum levels in non-diabetic ankylosing spondylitis patients. Annals of the Rheumatic Diseases 2013 10.1136/annrheumdis-2013-204484
33. O'Shea F. D., Tsui F. W. L., Chiu B., Tsui H. W., Yazdanpanah M., Inman R. D., Retinol (vitamin A) and retinol-binding protein levels are decreased in ankylosing spondylitis: clinical and genetic analysis. Journal of Rheumatology 2007 34 12 2457 2459 2-s2.0-36849024553 (Pubitemid 350230671)
34. Oh D. K., Ciaraldi T., Henry R. R., Adiponectin in health and disease. Diabetes, Obesity and Metabolism 2007 9 3 282 289 2-s2.0-33947663558 10.1111/j.1463-1326.2006.00610.x (Pubitemid 46502045)
35. Otero M., Logo R., Gomez R., Logo F., Dieguez C., Gómez-Reino J. J., Gualillo O., Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 2006 65 9 1198 1201 2-s2.0-33747786726 10.1136/ard.2005.046540 (Pubitemid 44277396)
36. Derdemezis C. S., Filippatos T. D., Voulgari P. V., Tselepis A. D., Drosos A. A., Kiortsis D. N., Leptin and adiponectin levels in patients with ankylosing spondylitis. The effect of infliximab treatment. Clinical and Experimental Rheumatology 2010 28 6 880 883 2-s2.0-79952654648
37. Miranda-Filloy J. A., López-Mejias R., Genre F., Adiponectin and resistin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF- α antagonist therapy. Clinical and Experimental Rheumatology 2013 31 3 365 371
38. Yamauchi T., Kamon J., Minokoshi Y., Ito Y., Waki H., Uchida S., Yamashita S., Noda M., Kita S., Ueki K., Eto K., Akanuma Y., Froguel P., Foufelle F., Ferre P., Carling D., Kimura S., Nagai R., Kahn B. B., Kadowaki T., Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nature Medicine 2002 8 11 1288 1295 2-s2.0-0036851817 10.1038/nm788 (Pubitemid 35373562)
39. Gonzalez-Gay M. A., Llorca J., Garcia-Unzueta M. T., Gonzalez-Juanatey C., De Matias J. M., Martin J., Redelinghuys M., Woodiwiss A. J., Norton G. R., Dessein P. H., High-grade inflammation, circulating adiponectin concentrations and cardiovascular risk factors in severe rheumatoid arthritis. Clinical and Experimental Rheumatology 2008 26 4 596 603 2-s2.0-52649173297
40. Neumann E., Frommer K. W., Vasile M., Müller-Ladner U., Adipocytokines as driving forces in rheumatoid arthritis and related inflammatory diseases? Arthritis and Rheumatism 2011 63 5 1159 1169 2-s2.0-79955556433 10.1002/art.30291
41. Hartman H. B., Hu X., Tyler K. X., Dalal C. K., Lazar M. A., Mechanisms regulating adipocyte expression of resistin. Journal of Biological Chemistry 2002 277 22 19754 19761 2-s2.0-0037205499 10.1074/jbc.M201451200 (Pubitemid 34967491)
42. Migita K., Maeda Y., Miyashita T., Kimura H., Nakamura M., Ishibashi H., Eguchi K., The serum levels of resistin in rheumatoid arthritis patients. Clinical and Experimental Rheumatology 2006 24 6 698 701 2-s2.0-33846438219 (Pubitemid 46138804)
43. Šenolt L., Housa D., Vernerová Z., Jirásek T., Svobodová R., Veigl D., Anderlová K., Müller-Ladner U., Pavelka K., Haluzík M., Resistin in rheumatoid arthritis synovial tissue, synovial fluid and serum. Annals of the Rheumatic Diseases 2007 66 4 458 463 2-s2.0-34147205638 10.1136/ard.2006.054734 (Pubitemid 46580464)
44. Gonzalez-Gay M. A., Garcia-Unzueta M. T., Gonzalez-Juanatey C., Miranda-Filloy J. A., Vazquez-Rodriguez T. R., de Matias J. M., Martin J., Dessein P. H., Llorca J., Anti-TNF- α therapy modulates resistin in patients with rheumatoid arthritis. Clinical and Experimental Rheumatology 2008 26 2 311 316 2-s2.0-43349098447 (Pubitemid 351659139)
45. Schäffler A., Ehling A., Neumann E., Herfarth H., Tarner I., Schölmerich J., Müller-Ladner U., Gay S., Adipocytokines in synovial fluid. Journal of the American Medical Association 2003 290 13 1709 1710 2-s2.0-0141816765 10.1001/jama.290.13.1709-c
46. Kocabas H., Kocabas V., Buyukbas S., Melikoglu M. A., Sezer I., Butun B., The serum levels of resistin in ankylosing spondylitis patients: a pilot study. Rheumatology International 2012 32 3 699 702 2-s2.0-78649708465 10.1007/s00296-010-1651-7
47. Fantuzzi G., Faggioni R., Leptin in the regulation of immunity, inflammation, and hematopoiesis. Journal of Leukocyte Biology 2000 68 4 437 446 2-s2.0-0033782028
48. Tilg H., Moschen A. R., Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nature Reviews Immunology 2006 6 10 772 783 2-s2.0-33748992313 10.1038/nri1937 (Pubitemid 44453463)
49. Targońska-Stpniak B., Dryglewska M., Majdan M., Adiponectin and leptin serum concentrations in patients with rheumatoid arthritis. Rheumatology International 2010 30 6 731 737 2-s2.0-77951024909 10.1007/s00296-009-1053-x
50. Gainsford T., Willson T. A., Metcalf D., Handman E., Mcfarlane C., Ng A., Nicola N. A., Alexander W. S., Hilton D. J., Leptin can induce proliferation, differentiation, and functional activation of hemopoietic cells. Proceedings of the National Academy of Sciences of the United States of America 1996 93 25 14564 14568 2-s2.0-0029952911 10.1073/pnas.93.25.14564 (Pubitemid 26419007)
51. Lord G. M., Matarese G., Howard J. K., Baker R. J., Bloom S. R., Lechler R. I., Leptin modulates the T-cell immune response and reverses starvation- induced immunosuppression. Nature 1998 394 6696 897 901 2-s2.0-0032572722 10.1038/29795 (Pubitemid 28410912)
52. Otero M., Lago R., Gómez R., Lago F., Gómez-Reino J. J., Gualillo O., Leptin: a metabolic hormone that functions like a proinflammatory adipokine. Drug News and Perspectives 2006 19 1 21 26 2-s2.0-33645380810 10.1358/dnp.2006.19.1.966243
53. Yoshino T., Kusunoki N., Tanaka N., Elevated serum levels of resistin, leptin, and adiponectin are associated with C-reactive protein and also other clinical conditions in rheumatoid arthritis. Internal Medicine 2011 50 4 269 275
54. Park M. C., Chung S. J., Park Y. B., Lee S. K., Pro-inflammatory effect of leptin on peripheral blood mononuclear cells of patients with ankylosing spondylitis. Joint Bone Spine 2009 76 2 170 175 2-s2.0-61649116369 10.1016/j.jbspin.2008.04.018
55. Sari I., Demir T., Kozaci L. D., Akar S., Kavak T., Birlik M., Onen F., Akkoc N., Body composition, insulin, and leptin levels in patients with ankylosing spondylitis. Clinical Rheumatology 2007 26 9 1427 1432 2-s2.0-34547581732 10.1007/s10067-006-0509-6 (Pubitemid 47193559)
56. Miranda-Filloy J. A., López-Mejias R., Genre F., Leptin and visfatin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF- α antagonist therapy. Clinical and Experimental Rheumatology 2013 31 4 538 545
57. Gonzalez-Gay M. A., Garcia-Unzueta M. T., Berja A., Gonzalez-Juanatey C., Miranda-Filloy J. A., Vazquez-Rodriguez T. R., Matias J. M. D., Martin J., Dessein P. H., Llorca J., Anti-TNF- α therapy does not modulate leptin in patients with severe rheumatoid arthritis. Clinical and Experimental Rheumatology 2009 27 2 222 228 2-s2.0-67249123828
58. Nicklas B. J., Gender differences in the response of plasma leptin concentrations to weight loss in obese older individuals. Obesity Research 1997 5 1 62 68 2-s2.0-0030637364 (Pubitemid 127702771)
59. Popa C., Netea M. G., De Graaf J., Van Den Hoogen F. H. J., Radstake T. R. D. J., Toenhake-Dijkstra H., Van Riel P. L. C. M., Van Der Meer J. W. M., Stalenhoef A. F. H., Barrera P., Circulating leptin and adiponectin concentrations during tumor necrosis factor blockade in patients with active rheumatoid arthritis. Journal of Rheumatology 2009 36 4 724 730 2-s2.0-66149104713 10.3899/jrheum.080626
60. Luk T., Malam Z., Marshall J. C., Pre-B cell colony-enhancing factor (PBEF)/visfatin: a novel mediator of innate immunity. Journal of Leukocyte Biology 2008 83 4 804 816 2-s2.0-44449124774 10.1189/jlb.0807581 (Pubitemid 351959859)
61. Fukuhara A., Matsuda M., Nishizawa M., Segawa K., Tanaka M., Kishimoto K., Matsuki Y., Murakami M., Ichisaka T., Murakami H., Watanabe E., Takagi T., Akiyoshi M., Ohtsubo T., Kihara S., Yamashita S., Makishima M., Funahashi T., Yamanaka S., Hiramatsu R., Matsuzawa Y., Shimomura I., Visfatin: a protein secreted by visceral fat that Mimics the effects of insulin. Science 2005 307 5708 426 430 2-s2.0-19944433652 10.1126/science.1097243 (Pubitemid 40139988)
62. Berndt J., Klöting N., Kralisch S., Kovacs P., Fasshauer M., Schön M. R., Stumvoll M., Blüher M., Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 2005 54 10 2911 2916 2-s2.0-25844491778 10.2337/diabetes.54.10.2911 (Pubitemid 41401086)
63. Brentano F., Schorr O., Ospelt C., Stanczyk J., Gay R. E., Gay S., Kyburz D., Pre-B cell colony-enhancing factor/visfatin, a new marker of inflammation in rheumatoid arthritis with proinflammatory and matrix-degrading activities. Arthritis and Rheumatism 2007 56 9 2829 2839 2-s2.0-34848847894 10.1002/art.22833 (Pubitemid 47502729)
64. Moschen A. R., Kaser A., Enrich B., Mosheimer B., Theurl M., Niederegger H., Tilg H., Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. Journal of Immunology 2007 178 3 1748 1758 2-s2.0-33846527541 (Pubitemid 46154646)
65. Hulejová H., Levitová A., Kuklová M., Štochl J., Haluzík M., Pavelka K., Vencovský J., Šenolt L., No effect of physiotherapy on the serum levels of adipocytokines in patients with ankylosing spondylitis. Clinical Rheumatology 2012 31 1 67 71 2-s2.0-84856704589 10.1007/s10067-011-1773-7
66. Gonzalez-Gay M. A., Vazquez-Rodriguez T. R., Garcia-Unzueta M. T., Berja A., Miranda-Filloy J. A., De Matias J. M., Gonzalez-Juanatey C., Llorca J., Visfatin is not associated with inflammation or metabolic syndrome in patients with severe rheumatoid arthritis undergoing anti-TNF- α therapy. Clinical and Experimental Rheumatology 2010 28 1 56 62 2-s2.0-77949508778
67. Kowalska I., Straczkowski M., Nikolajuk A., Adamska A., Karczewska-Kupczewska M., Otziomek E., Wolczynski S., Gorska M., Serum visfatin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome. Human Reproduction 2007 22 7 1824 1829 2-s2.0-34447336403 10.1093/humrep/dem118 (Pubitemid 47062747)
68. Kidoya H., Takakura N., Biology of the apelin-APJ axis in vascular formation. Journal of Biochemistry 2012 152 2 125 131
69. Japp A. G., Cruden N. L., Amer D. A. B., Li V. K. Y., Goudie E. B., Johnston N. R., Sharma S., Neilson I., Webb D. J., Megson I. L., Flapan A. D., Newby D. E., Vascular effects of apelin in vivo in man. Journal of the American College of Cardiology 2008 52 11 908 913 2-s2.0-50349086725 10.1016/j.jacc.2008. 06.013
70. Boucher J., Masri B., Daviaud D., Gesta S., Guigné C., Mazzucotelli A., Castan-Laurell I., Tack I., Knibiehler B., Carpé né C., Audigier Y., Saulnier-Blache J.-S., Valet P., Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology 2005 146 4 1764 1771 2-s2.0-20144380036 10.1210/en.2004-1427 (Pubitemid 40396885)
71. Tasci I., Dogru T., Naharci I., Erdem G., Yilmaz M. I., Sonmez A., Bingol N., Kilic S., Bingol S., Erikci S., Plasma apelin is lower in patients with elevated LDL-cholesterol. Experimental and Clinical Endocrinology and Diabetes 2007 115 7 428 432 2-s2.0-34547819801 10.1055/s-2007-971067 (Pubitemid 47234642)
72. Malyszko J., Malyszko J. S., Pawlak K., Mysliwiec M., Visfatin and apelin, new adipocytokines, and their relation to endothelial function in patients with chronic renal failure. Advances in Medical Sciences 2008 53 1 32 36 2-s2.0-55249089945 10.2478/v10039-008-0024-x
73. Li Z., Bai Y., Hu J., Reduced apelin levels in stable angina. Internal Medicine 2008 47 22 1951 1955 2-s2.0-59849116214 10.2169/internalmedicine.47. 1287
74. Li L., Yang G., Li Q., Tang Y., Yang M., Yang H., Li K., Changes and relations of circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects. Experimental and Clinical Endocrinology and Diabetes 2006 114 10 544 548 2-s2.0-33846138616 10.1055/s-2006-948309 (Pubitemid 46087259)
75. Erdem G., Dogru T., Tasci I., Sonmez A., Tapan S., Low plasma apelin levels in newly diagnosed type 2 diabetes mellitus. Experimental and Clinical Endocrinology and Diabetes 2008 116 5 289 292 2-s2.0-44849097514 10.1055/s-2007-1004564 (Pubitemid 351798738)
76. di Franco M., Spinelli F. R., Metere A., Serum levels of asymmetric dimethylarginine and apelin as potential markers of vascular endothelial dysfunction in early rheumatoid arthritis. Mediators of Inflammation 2012 2012 7 347268 10.1155/2012/347268
77. Genre F., Miranda-Filloy J. A., López-Mejias R., Apelin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF- α antagonist therapy. Clinical and Experimental Rheumatology 2013 31 4 532 537
78. Ferraz-Amaro I., Arce-Franco M., Muiz J., Lpez-Fernndez J., Hernndez-Hernndez V., Franco A., Quevedo J., Martnez-Martn J., Daz-Gonzlez F., Systemic blockade of TNF- α does not improve insulin resistance in humans. Hormone and Metabolic Research 2011 43 11 801 808 2-s2.0-80054848953 10.1055/s-0031-1287783
79. Deanfield J. E., Halcox J. P., Rabelink T. J., Endothelial function and dysfunction: testing and clinical relevance. Circulation 2007 115 10 1285 1295 2-s2.0-33947716172 10.1161/CIRCULATIONAHA.106.652859 (Pubitemid 46594773)
80. Tousoulis D., Kampoli A.-M., Papageorgiou C. T. N., Stefanadis C., The role of nitric oxide on endothelial function. Current Vascular Pharmacology 2012 10 1 4 18 2-s2.0-84857129673 10.2174/157016112798829760
81. Vallance P., Chan N., Endothelial function and nitric oxide: clinical relevance. Heart 2001 85 3 342 350 2-s2.0-0034758378 (Pubitemid 32973574)
82. Sibal L., Agarwal S. C., Home P. D., Boger R. H., The role of asymmetric dimethylarginine (ADMA) in endothelial dysfunction and cardiovascular disease. Current Cardiology Reviews 2010 6 2 82 90 2-s2.0-77951642455 10.2174/157340310791162659
83. Böger R. H., The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. Cardiovascular Research 2003 59 4 824 833 2-s2.0-0842347848 10.1016/S0008-6363(03)00500-5 (Pubitemid 38366238)
84. Surdacki A., Nowicki M., Sandmann J., Tsikas D., Boeger R. H., Bode-Boeger S. M., Kruszelnicka-Kwiatkowska O., Kokot F., Dubiel J. S., Froelich J. C., Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. Journal of Cardiovascular Pharmacology 1999 33 4 652 658 2-s2.0-0032912757 10.1097/00005344-199904000-00020 (Pubitemid 29164831)
85. Lundman P., Eriksson M. J., Stühlinger M., Cooke J. P., Hamsten A., Tornvall P., Mild-to-moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine. Journal of the American College of Cardiology 2001 38 1 111 116 2-s2.0-0034975920 10.1016/S0735-1097(01)01318-3 (Pubitemid 32613836)
86. Böger R. H., Bode-Böger S. M., Szuba A., Tsao P. S., Chan J. R., Tangphao O., Blaschke T. F., Cooke J. P., Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998 98 18 1842 1847 2-s2.0-0242322346 (Pubitemid 28509278)
87. Abbasi F., Asagmi T., Cooke J. P., Lamendola C., McLaughlin T., Reaven G. M., Stuehlinger M., Tsao P. S., Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. The American Journal of Cardiology 2001 88 10 1201 1203 2-s2.0-0035889591 10.1016/S0002-9149(01)02063-X (Pubitemid 33043860)
88. Stühlinger M. C., Abbasi F., Chu J. W., Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. The Journal of the American Medical Association 2002 287 11 1420 1426 (Pubitemid 34250505)
89. Sari I., Kebapcilar L., Alacacioglu A., Bilgi O., Yildiz Y., Taylan A., Yukel A., Kozaci D. L., Increased levels of asymmetric dimethylarginine (ADMA) in patients with ankylosing spondylitis. Internal Medicine 2009 48 16 1363 1368 2-s2.0-70349546855 10.2169/internalmedicine.48.2193
90. Kemény-Beke Á., Gesztelyi R., Bodnár N., Zsuga J., Kerekes G., Zsuga M., Biri B., Kéki S., Szodoray P., Berta A., Szekanecz Z., Szántó S., Increased production of asymmetric dimethylarginine (ADMA) in ankylosing spondylitis: association with other clinical and laboratory parameters. Joint Bone Spine 2011 78 2 184 187 2-s2.0-79952242688 10.1016/j.jbspin.2010.05.009
91. Erre G. L., Sanna P., Zinellu A., Ponchietti A., Fenu P., Sotgia S., Carru C., Ganau A., Passiu G., Plasma asymmetric dimethylarginine (ADMA) levels and atherosclerotic disease in ankylosing spondylitis: a cross-sectional study. Clinical Rheumatology 2011 30 1 21 27 2-s2.0-79151475070 10.1007/s10067-010- 1589-x
92. Genre F., López-Mejías R., Miranda-Filloy J. A., Asymmetric dimethylarginine serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF- α antagonist therapy. Clinical and Experimental Rheumatology 2013 31 5 749 755
93. Popa C., van den Hoogen F. H., Radstake T. R., Netea M. G., Eijsbouts A. E., den Heijer M., van der Meer J. W. M., van Riel P. L. C. M., Stalenhoef A. F. H., Barrera P., Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis. Annals of the Rheumatic Diseases 2007 66 11 1503 1507 2-s2.0-34848912752 10.1136/ard.2006.066191 (Pubitemid 350032660)
94. Popa C. D., Arts E., Fransen J., van Riel P. L., Atherogenic index and high-density lipoprotein cholesterol as cardiovascular risk determinants in rheumatoid arthritis: the impact of therapy with biologicals. Mediators of Inflammation 2012 2012 9 10.1155/2012/785946 785946
95. Angel K., Provan S. A., Mowinckel P., Seljeflot I., Kvien T. K., Atar D., The L-arginine/asymmetric dimethylarginine ratio is improved by anti-tumor necrosis factor- α therapy in inflammatory arthropathies. Associations with aortic stiffness. Atherosclerosis 2012 225 1 160 165
96. Korkosz M., Ga̧sowski J., Surdacki A., Disparate effects of anti-TNF- α therapies on measures of disease activity and mediators of endothelial damage in ankylosing spondylitis. Pharmacological Reports 2013 65 4 891 897
97. Westra J., de Groot L., Plaxton S. L., Brouwer E., Posthumus M. D., Kallenberg C. G. M., Bijl M., Angiopoietin-2 is highly correlated with inflammation and disease activity in recent-onset rheumatoid arthritis and could be predictive for cardiovascular disease. Rheumatology 2011 50 4 665 673 2-s2.0-79952777526 10.1093/rheumatology/keq378
98. López-Mejías R., Corrales A., Genre F., Angiopoietin-2 serum levels correlate with severity, early onset and cardiovascular disease in patients with rheumatoid arthritis. Clinical and Experimental Rheumatology 2013 31 5 761 766
99. Genre F., Miranda-Filloy J. A., López-Mejias R., Antitumour necrosis factor- α therapy modulates angiopoietin-2 serum levels in non-diabetic ankylosing spondylitis patients. Annals of the Rheumatic Diseases 2013 72 7 1265 1267
100. Krausz S., Garcia S., Ambarus C. A., Angiopoietin-2 promotes inflammatory activation of human macrophages and is essential for murine experimental arthritis. Annals of the Rheumatic Diseases 2012 71 8 1402 1410
101. Greenberg J. D., Kremer J. M., Curtis J. R., Hochberg M. C., Reed G., Tsao P., Farkouh M. E., Nasir A., Setoguchi S., Solomon D. H., Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 2011 70 4 576 582 2-s2.0-79952351318 10.1136/ard.2010.129916
102. Choi S. T., Kim J. H., Kang E. J., Lee S. W., Park M. C., Park Y. B., Lee S. K., Osteopontin might be involved in bone remodelling rather than in inflammation in ankylosing spondylitis. Rheumatology 2008 47 12 1775 1779 2-s2.0-56649122122 10.1093/rheumatology/ken385
103. Briggs T. A., Osteopontin-a biomarker for organ damage in paediatric lupus? Arthritis Research & Therapy 2013 15 2, article 110 10.1186/ar4172
104. Haylock D. N., Nilsson S. K., Osteopontin: a bridge between bone and blood. British Journal of Haematology 2006 134 5 467 474 2-s2.0-33746578393 10.1111/j.1365-2141.2006.06218.x (Pubitemid 44141712)
105. Gürsoy G., Alagöz S., Acar Y., Demirbaş B., Çetiner H., Kiliç Z., Osteopontin a new probable marker for atherosclerosis in obese women? Clinical Reviews and Opinions 2010 2 3 35 40
106. Golledge J., McCann M., Mangan S., Lam A., Karan M., Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis. Stroke 2004 35 7 1636 1641 2-s2.0-3042546950 10.1161/01.STR.0000129790.00318.a3 (Pubitemid 38823639)
107. Genre F., López-Mejias R., Miranda-Filloy J. A., Correlation between two biomarkers of atherosclerosis, osteopontin and angiopoyetin-2, in non-diabetic ankylosing spondylitis patients undergoing TNF- α antagonist therapy. Clinical and Experimental Rheumatology. In press
108. Kwiatkowski D. J., Mehl R., Izumo S., Nadal-Ginard B., Yin H. L., Muscle is the major source of plasma gelsolin. Journal of Biological Chemistry 1988 263 17 8239 8243 2-s2.0-0023899912
109. Osborn T. M., Verdrengh M., Stossel T. P., Bokarewa M., Decreased levels of the gelsolin plasma isoform in patients with rheumatoid arthritis. Arthritis Research & Therapy 2008 10 5, article R117 2-s2.0-54349108155 10.1186/ar2520
110. Huang L. F., Yao Y. M., Li J. F., Dong N., Liu C., Yu Y., He L. X., Sheng Z. Y., Reduction of plasma gelsolin levels correlates with development of multiple organ dysfunction syndrome and fatal outcome in burn patients. PLoS ONE 2011 6 11 10.1371/journal.pone.0025748 e25748 2-s2.0-84858192505
111. Aidinis V., Carninci P., Armaka M., Witke W., Harokopos V., Pavelka N., Koczan D., Argyropoulos C., Thwin M.-M., Möller S., Waki K., Gopalakrishnakone P., Ricciardi-Castagnoli P., Thiesen H.-J., Hayashizaki Y., Kollias G., Cytoskeletal rearrangements in synovial fibroblasts as a novel pathophysiological determinant of modeled rheumatoid arthritis. PLoS Genetics 2005 1 4, article e48 2-s2.0-33746012370
112. Genre F., López-Mejias R., Miranda-Filloy J. A., Gelsolin levels are decreased in ankylosing spondylitis patients undergoing anti-TNF-alpha therapy. Clinical and Experimental Rheumatology. In press
113. Hofbauer L. C., Schoppet M., Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. The Journal of the American Medical Association 2004 292 4 490 495 2-s2.0-3242781731 10.1001/jama.292.4.490 (Pubitemid 38988958)
114. van Campenhout A., Golledge J., Osteoprotegerin, vascular calcification and atherosclerosis. Atherosclerosis 2009 204 2 321 329 2-s2.0-67349099856 10.1016/j.atherosclerosis.2008.09.033
115. Secchiero P., Corallini F., Beltrami A. P., Ceconi C., Bonasia V., Di Chiara A., Ferrari R., Zauli G., An imbalanced OPG/TRAIL ratio is associated to severe acute myocardial infarction. Atherosclerosis 2010 210 1 274 277 2-s2.0-77952427166 10.1016/j.atherosclerosis.2009.11.005
116. Secchiero P., Rimondi E., di Lasio M. G., C-reactive protein downregulates TRAIL expression in human peripheral monocytes via an Egr-1-dependent pathway. Clinical Cancer Research 2013 19 8 1949 1959
117. di Bartolo B. A., Cartland S. P., Harith H. H., Bobryshev Y. V., Schoppet M., Kavurma M. M., TRAIL-deficiency accelerates vascular calcification in atherosclerosis via modulation of RANKL. PLoS ONE 2013 8 9 e74211 10.1371/journal.pone.0074211
118. Mangan S. H., Campenhout A. V., Rush C., Golledge J., Osteoprotegerin upregulates endothelial cell adhesion molecule response to tumor necrosis factor- α associated with induction of angiopoietin-2. Cardiovascular Research 2007 76 3 494 505 2-s2.0-35548975135 10.1016/j.cardiores.2007.07.017
119. Kiechl S., Schett G., Wenning G., Redlich K., Oberhollenzer M., Mayr A., Santer P., Smolen J., Poewe W., Willeit J., Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 2004 109 18 2175 2180 2-s2.0-2442492972 10.1161/01.CIR.0000127957.43874.BB (Pubitemid 38625393)
120. Dessein P. H., López-Mejias R. L., González-Juanatey C., Independent relationship of osteoprotegerin concentrations with endothelial activation and carotid atherosclerosis in patients with severe rheumatoid arthritis. The Journal of Rheumatology 2014 10.3899/jrheum.131037
121. Genre F., López-Mejias R., Miranda-Filloy J. A., Osteoprotegerin correlates with disease activity and endothelial activation in non-diabetic ankylosing spondylitis patients undergoing TNF- α antagonist therapy. Clinical and Experimental Rheumatology. In press